Business Description
Founded in 1978 and based in Cambridge, Massachusetts, Biogen researches, develops, and sells treatments for serious neurological and rare diseases across the United States, Europe, Asia, and other global markets. Its portfolio includes medicines for conditions such as multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and several blood and autoimmune disorders. The company also works with a broad network of partners, including Eisai, Genentech, Ionis Pharmaceuticals, and Samsung Bioepis, to advance new therapies and expand its range of treatments.